The Ahmedabad-based firm has fixed Wednesday, November 4, as the record date to determine investor eligibility for its 1:1 bonus issue. Under this arrangement, shareholders will receive one additional equity share for every fully paid-up share they currently own, pending necessary regulatory and statutory clearances. Despite shedding approximately 14.28% over the past year, the company's shares closed Friday at ₹1,245.30, maintaining significant long-term growth above the original IPO issue price of ₹741.
Key points
Shareholders must own Concord Biotech stock by Tuesday, November 3, to be deemed eligible…: Shareholders must own Concord Biotech stock by Tuesday, November 3, to be deemed eligible on the official November 4 record date.
The corporate action stands as the sole bonus share issue scheduled on the BSE calendar f…: The corporate action stands as the sole bonus share issue scheduled on the BSE calendar for the upcoming week.
Long-term gains persist even though the stock has declined by 9.33% over the past month a…: Long-term gains persist even though the stock has declined by 9.33% over the past month and 14.28% over one year.
Sources checked by our analysis pipeline: 1
Bonus issue record date this week: Shares of Concord Biotech Limited will remain in focus next week due to their upcoming record date for the issuance of bonus shares to eligible investors. The Ahmedabad-headquartered bio-pharmaceutical components manufacturer has fixed Wednesday as the record date for bonus issue.
Shares of Concord Biotech ended higher on Friday as part of overall bullish sentiment prevailing across the pharmaceutical sector stocks through the week. As the bonus issue record date approaches, here are all the details about the corporate earnings.
Concord Biotech bonus issue
The company’s board of directors approved a bonus issue in the ratio of 1:1. Which means that every shareholder will receive one equity share for every one existing fully paid up shares held. The issuance of additional shares will be subject to statutory and regulatory approvals.
Concord Biotech bonus issue record date
It is the only bonus issue record date scheduled for the coming week, as per BSE website data as on November 1. The company has fixed Wednesday, November 4, as the record date to determine eligibility of shareholders…
A sharp market downturn following gold's worst-ever October performance has triggered heavy selling across both domestic and international precious metals markets. Heightened expectations of a December Federal Reserve rate hike and sticky inflation figures have severely undermined investor appetite for non-yielding assets. Consequently, prices are extending their decline toward levels not seen since late 2025 as macroeconomic pressures mount.
Utssav CZ Gold Jewels is rewarding investors by funding a capital expansion through its securities premium, free reserves, and retained earnings. This corporate action will effectively double the jewellery manufacturer's existing paid-up capital and outstanding shares once regulatory clearances are secured. Despite recent technical pullbacks, the move reflects substantial balance sheet strength built during an aggressive multi-fold market rally this year.
Robust economic activity and a sharp surge in imports provided a significant boost to India's fiscal receipts during the month. Net revenue experienced an even stronger expansion after accounting for taxpayer refunds, indicating healthy underlying consumption trends. Major state economies across the nation maintained solid growth trajectories, with smaller regions posting substantial momentum in their tax intake.